Prelude Therapeutics: A Promising Player in Precision Oncology

Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025. The company will be represented by its key executives, including Kris Vaddi, Ph.D., Chief Executive Officer, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer, who will participate in a fireside chat at 12:30 p.m. ET. The event will be accessible via live webcast on the Company’s website under Events and Presentations, with the recording archived for 90 days.

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Its pipeline is comprised of several novel drug candidates, including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. The company is also leveraging its expertise in targeted protein degradation to discover, develop, and commercialize next-generation degrader antibody conjugates (Precision ADCs) with partners.

The company's participation in the Barclays conference provides an opportunity for investors and industry professionals to learn more about Prelude's progress, pipeline, and strategic goals. During the fireside chat, Prelude's executives are expected to discuss the company's recent clinical data, partnerships, and future plans. Some key topics that may be addressed include:

1. Clinical progress and data: Prelude has reported encouraging signs of anti-tumor activity and a generally well-tolerated safety profile in early clinical trials of its SMARCA2 degraders. The company may provide updates on these trials and any new data that has emerged since the last public announcement.
2. Partnerships and collaborations: Prelude has established partnerships to develop next-generation degrader antibody conjugates (Precision ADCs) with other companies. The company may discuss any new partnerships or collaborations that have been formed, as well as the progress made in these partnerships.
3. Future plans and growth strategies: Prelude's executives may outline the company's plans for expanding its pipeline, entering new indications, or exploring new therapeutic areas. They may also discuss the company's strategy for commercializing its products and bringing them to market.



Prelude Therapeutics' focus on precision oncology and targeted protein degradation positions it uniquely in the competitive biotech landscape. By developing innovative medicines in areas of high unmet need for cancer patients, the company is well-positioned to address the growing demand for more effective and less toxic treatments. The company's participation in the Barclays conference is an excellent opportunity for investors to learn more about Prelude's progress and potential as a leading player in the precision oncology space.